TABLE 2.
Multivariable analysis logistic regression for LUAD patients with specific organ metastases
| Variables | LUAD patients | Specific organ metastatic cohort | P | Bone metastatic cohort | P | ||
|---|---|---|---|---|---|---|---|
| N = 40 117 | N = 17 529 | Odds ratio | N = 9440 | Odds ratio | |||
| N (%) | N (%) | OR (95% CI) | N (%) | OR (95% CI) | |||
| Diagnosed years | |||||||
| 2010–2012 | 18 116 (45.16%) | 7835 (44.70%) | 1 | NA | 4101 (43.44%) | 1 | NA |
| 2013–2015 | 22 001 (54.84%) | 9694 (55.30%) | 0.93 (0.89–0.97) | <0.01 | 5339 (56.56%) | 0.88 (0.84–0.93) | <0.01 |
| Sex | |||||||
| Male | 19 109 (47.63%) | 8936 (50.98%) | 1 | NA | 5059 (53.59%) | 1 | NA |
| Female | 21 008 (52.37%) | 8593 (49.02%) | 1.17 (1.12–1.22) | <0.01 | 4381 (46.41%) | 1.29 (1.23–1.36) | <0.01 |
| Diagnosed age | |||||||
| 18–45 | 1001 (2.50%) | 583 (3.33%) | 1 | NA | 325 (3.44%) | 1 | NA |
| 46–70 | 23 938 (59.67%) | 10 908 (62.23%) | 1.43 (1.25–1.65) | <0.01 | 5889 (62.38%) | 1.30 (1.12–1.49) | <0.01 |
| >70 | 15 178 (37.83%) | 6038 (34.45%) | 1.68 (1.46–1.93) | <0.01 | 3226 (34.17%) | 1.47 (1.27–1.70) | <0.01 |
| Marital status | |||||||
| Married | 33 857 (84.40%) | 14 576 (83.15%) | 1 | NA | 7937 (84.08%) | 1 | NA |
| Unmarried | 6260 (15.60%) | 2953 (16.85%) | 0.92 (0.86–0.97) | <0.01 | 1503 (15.92%) | 1.03 (0.96–1.10) | 0.37 |
| Insurance, PRCDA | |||||||
| Yes | 10 826 (26.99%) | 4816 (27.47%) | 1 | NA | 2580 (27.33%) | 1 | NA |
| No | 29 291 (73.01%) | 12 713 (72.53%) | 1.06 (1.01–1.12) | 0.02 | 6860 (72.67%) | 1.03 (0.97–1.09) | 0.32 |
| Race, ethnicity | |||||||
| White | 31 135 (77.61%) | 13 450 (76.73%) | 1 | NA | 7290 (77.22%) | 1 | NA |
| American Indian | 188 (0.47%) | 94 (0.54%) | 0.90 (0.66–1.24) | 0.53 | 48 (0.51%) | 1.01 (0.72–1.43) | 0.94 |
| Asian or PI | 3776 (9.41%) | 1758 (10.03%) | 0.90 (0.84–0.97) | 0.01 | 989 (10.48%) | 0.90 (0.83–0.97) | 0.01 |
| Black | 5018 (12.51%) | 2227 (12.70%) | 1.10 (1.03–1.17) | 0.01 | 1113 (11.79%) | 1.17 (1.08–1.26) | <0.01 |
| Laterality | |||||||
| Left | 16 017 (39.93%) | 7169 (40.90%) | 1 | NA | 3951 (41.85%) | 1 | NA |
| Right | 24 100 (60.07%) | 10 360 (59.10%) | 1.13 (1.08–1.18) | <0.01 | 5489 (58.15%) | 1.15 (1.09–1.20) | <0.01 |
| Primary site | |||||||
| Upper lobe | 24 825 (61.88%) | 10 632 (60.65%) | 1 | NA | 5623 (59.57%) | 1 | NA |
| Middle lobe | 2091 (5.21%) | 910 (5.19%) | 0.92 (0.83–1.02) | 0.10 | 481 (5.10%) | 0.92 (0.82–1.03) | 0.14 |
| Lower lobe | 11 596 (28.91%) | 5076 (28.96%) | 0.90 (0.86–0.94) | <0.01 | 2849 (30.18%) | 0.86 (0.81–0.91) | <0.01 |
| Overlapping | 440 (1.10%) | 200 (1.14%) | 1.19 (0.98–1.46) | 0.09 | 92 (0.97%) | 1.28 (1.01–1.63) | 0.04 |
| Main bronchus | 1165 (2.90%) | 711 (4.06%) | 0.76 (0.67–0.87) | <0.01 | 395 (4.18%) | 0.79 (0.69–0.89) | <0.01 |
| Brain metastatic cohort | P | Liver metastatic cohort | P | Lung metastatic cohort | P | |||
|---|---|---|---|---|---|---|---|---|
| N = 7167 | Odds ratio | N = 3784 | Odds ratio | N = 6661 | Odds ratio | |||
| N (%) | OR (95% CI) | N (%) | OR (95% CI) | N (%) | OR (95% CI) | |||
| 3180 (44.37%) | 1 | NA | 1689 (44.64%) | 1 | NA | 2978 (44.71%) | 1 | NA |
| 3987 (55.63%) | 0.94 (0.89–0.99) | 0.02 | 2095 (55.36%) | 0.96 (0.89–1.02) | 0.20 | 3683 (55.29%) | 0.96 (0.90–1.01) | 0.14 |
| 3467 (48.37%) | 1 | NA | 1956 (51.69%) | 1 | NA | 3315 (49.77%) | 1 | NA |
| 3700 (51.63%) | 0.95 (0.90–1.00) | 0.07 | 1828 (48.31%) | 1.12 (1.04–1.20) | <0.01 | 3346 (50.23%) | 0.98 (0.93–1.04) | 0.58 |
| 285 (3.98%) | 1 | NA | 115 (3.04%) | 1 | NA | 218 (3.27%) | 1 | NA |
| 4983 (69.53%) | 1.33 (1.15–1.53) | <0.01 | 2361 (62.39%) | 1.02 (0.84–1.25) | 0.82 | 3918 (58.82%) | 1.14 (0.96–1.35) | 0.13 |
| 1899 (26.50%) | 2.34 (2.01–2.72) | <0.01 | 1308 (34.57%) | 1.10 (0.90–1.36) | 0.35 | 2525 (37.91%) | 0.99 (0.83–1.18) | 0.91 |
| 5872 (81.93%) | 1 | NA | 3164 (83.62%) | 1 | NA | 5550 (83.32%) | 1 | NA |
| 1295 (18.07%) | 0.90 (0.83–0.96) | <0.01 | 620 (16.38%) | 0.97 (0.89–1.07) | 0.60 | 1111 (16.68%) | 0.96 (0.89–1.04) | 0.36 |
| 1936 (27.01%) | 1 | NA | 1026 (27.11%) | 1 | NA | 1978 (29.70%) | 1 | NA |
| 5231 (72.99%) | 1.01 (0.95–1.07) | 0.74 | 2758 (72.89%) | 1.00 (0.92–1.08) | 0.97 | 4683 (70.30%) | 1.21 (1.13–1.29) | <0.01 |
| 5494 (76.66%) | 1 | NA | 2953 (78.04%) | 1 | NA | 4944 (74.22%) | 1 | NA |
| 41 (0.57%) | 0.89 (0.62–1.27) | 0.51 | 20 (0.53%) | 0.99 (0.61–1.58) | 0.95 | 44 (0.66%) | 0.76 (0.52–1.11) | 0.16 |
| 766 (10.69%) | 0.86 (0.79–0.94) | <0.01 | 369 (9.75%) | 1.01 (0.90–1.13) | 0.92 | 820 (12.31%) | 0.67 (0.62–0.74) | <0.01 |
| 866 (12.08%) | 1.20 (1.11–1.31) | <0.01 | 442 (11.68%) | 1.18 (1.06–1.32) | <0.01 | 853 (12.81%) | 1.02 (0.93–1.11) | 0.68 |
| 2922 (40.77%) | 1 | NA | 1547 (40.88%) | 2766 (41.53%) | 1 | NA | ||
| 4245 (59.23%) | 1.07 (1.01–1.13) | 0.02 | 2237 (59.12%) | 1.07 (1.00–1.15) | 0.06 | 3895 (58.47%) | 1.15 (1.08–1.22) | <0.01 |
| 4473 (62.41%) | 1 | NA | 2188 (57.82%) | 1 | NA | 3944 (59.21%) | 1 | NA |
| 370 (5.16%) | 1.01 (0.89–1.14) | 0.89 | 183 (4.84%) | 0.97 (0.83–1.15) | 0.74 | 366 (5.49%) | 0.81 (0.71–0.92) | <0.01 |
| 1973 (27.53%) | 1.04 (0.98–1.1) | 0.24 | 1172 (30.97%) | 0.83 (0.77–0.89) | <0.01 | 1966 (29.52%) | 0.83 (0.78–0.89) | <0.01 |
| 63 (0.88%) | 1.55 (1.18–2.04) | <0.01 | 49 (1.29%) | 0.89 (0.65–1.20) | 0.44 | 101 (1.52%) | 0.90 (0.70–1.14) | 0.38 |
| 288 (4.02%) | 0.89 (0.77–1.03) | 0.11 | 192 (5.07%) | 0.67 (0.57–0.79) | <0.01 | 284 (4.26%) | 0.98 (0.84–1.13) | 0.75 |
Abbreviations: CI, confidence interval; LUAD, lung adenocarcinoma; OR, odds ratio; NA, not applicable; PI, pacific islander; PRCDA, purchased/referred care delivery area.